Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Celgene
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Understand and voluntarily sign an informed consent form, if applicable, and have never been previously treated with pomalidomide before their inclusion in the Registry.
Patients with symptomatic, measurable relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both bortezomib and lenalidomide and have demonstrated disease progression on the last therapy and are commencing a pomalidomide based treatment.
You may not be if
Refusal to participate in the Registry or currently participating in the treatment phase of an interventional clinical trial.
Pregnancy.
Women of childbearing potential, unless all the conditions of the pregnancy prevention program are met.
Male patients unable to follow or comply with the required contraceptive measures.
Hypersensitivity to the active substance or to any of the excipients.
